Covid19, SARS-CoV-2 Infection
Conditions
Keywords
COVID-19, Montelukast
Brief summary
The current study aimed to make a therapeutic comparison and effectiveness of Hydroxychloroquine (HCQ) and Montelukast (ML) in COVID-19 patients in addition to the standard of care. The safety and efficacy of HCQ and ML will be assessed as individual therapy and in combination with each other and with the standard of care. Cytokine storm (Interleukin levels) also will be monitored throughout the study to assess treatment progression.
Detailed description
To date, no specific medication is available for COVID-19. Many FDA-approved drugs, including antivirals, antibacterials, and anti-inflammatory compositions are being tested with the intention of repurposing against COVID-19. In this study, investigators have evaluated the effectiveness of Hydroxychloroquine (HCQ) and Montelukast (ML) in an individual and combination therapy. Investigators have performed an observational study of 100 hospitalized COVID-19 patients while assessing the safety and efficacy of HCQ, ML, and IV as individual therapy and in combination with each other. ECG, interleukin levels, LFTs, blood profiles were continuously monitored throughout the study. The aim was to observe participants treated with ML and monitor the inflammatory markers to see whether they increase or decrease and whether an increase in survival rate is observed. The findings have shown that combinational therapy of ML with continuous observation of liver/kidney profiles and QTc prolongation can provide robust recovery with suppression of cytokines.
Interventions
DRUGMontelukast
An FDA approved medicine to treat asthmatic patients
DRUGHydroxychloroquine
An FDA approved antiarthritis drug
DRUGIvermectin
An FDA approved anti-parasitic medicine
Sponsors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shaukat Khanum Memorial Cancer Hospital & Research Centre
Shanghai Jiao Tong University School of Medicine
Teesside University
University of Sargodha
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with diagnosed COVID-19 * Patients who are not directly admitted to ICU
Exclusion criteria
* Patients, who were already on immunosuppressants * Patients with age \> 80 * Patient with any known allergies to montelukast
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients admittance to ICU | 2 Week | Changes in the number of ICU visits of COVID-19 patients |
| Length of total stay at the hospital | 2 weeks | Changes in the length of total stay of patients at the hospital |
| Alleviating the symptoms of COVID-19 | 2 weeks | Monitoring the changes in disease severity with alleviation of the symptoms |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Interleukin levels | 1 Week | Monitoring the Interleukin levels with the progression of treatments |
Countries
China, Pakistan
Outcome results
None listed